EBIT at other companies
Other financials
Where this comes from
Calculated from Tarsus Pharmaceuticals, Inc.’s reported figures.
Plus components not separately reported this period.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s ebit.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s EBIT?
- Tarsus Pharmaceuticals, Inc. (TARS) reported EBIT of -$6.12M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s EBIT changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s EBIT increased by 76.7% year-over-year, from -$26.28M to -$6.12M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s EBIT?
- Over 4 years (2021 to 2025), Tarsus Pharmaceuticals, Inc.'s EBIT has grown at a 55.4% compound annual growth rate (CAGR), from -$12.16M to -$70.97M.
- What does EBIT mean?
- Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.